A new monthly weight loss drug, MariTide, helped people shed up to 20% of body weight in a Phase 2 trial—comparable to Wegovy ...

GLP-1 agonists like Ozmepic may provide protection against dementia. A recent study suggests that semaglutide, found in ...

Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

FAIR Health data released this month showed more than 2% of adult patients now take a GLP-1 drug to treat overweight or obesity. Among all adult patients, the percentage who had an overweight or ...

ONE HEMP – a coalition of industry leaders committed to advancing regulatory standards for hemp-derived cannabinoid (CBD) products – issued a statement of strong support for Governor Greg Abbott's ...

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...

Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to ...

A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

NVO ends its deal with HIMS over safety concerns tied to compounded Wegovy, hitting patient access and market share plans.

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications ...